Aclaris Therapeutics (NASDAQ:ACRS) Stock Gets Price Target Trim from Wedbush

Aclaris Therapeutics (NASDAQ:ACRS) had its price objective decreased by Wedbush from $10.00 to $8.00 in a report issued on Wednesday morning,Benzinga reports. Wedbush currently has an outperform rating on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the company. Canaccord Genuity Group assumed coverage on Aclaris Therapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $10.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Finally, Wall Street Zen upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aclaris Therapeutics currently has an average rating of “Buy” and a consensus target price of $11.00.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $3.97 on Wednesday. The stock’s 50-day simple moving average is $4.88 and its 200-day simple moving average is $4.52. Aclaris Therapeutics has a 52 week low of $2.10 and a 52 week high of $6.60.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%. The firm had revenue of $1.63 million during the quarter, compared to analyst estimates of $1.38 million. Research analysts predict that Aclaris Therapeutics will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Aclaris Therapeutics in the second quarter worth about $53,096,000. Rock Springs Capital Management LP lifted its position in shares of Aclaris Therapeutics by 0.4% in the first quarter. Rock Springs Capital Management LP now owns 4,472,650 shares of the biotechnology company’s stock worth $16,772,000 after buying an additional 18,909 shares in the last quarter. Braidwell LP lifted its position in shares of Aclaris Therapeutics by 26.1% in the second quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company’s stock worth $11,333,000 after buying an additional 443,232 shares in the last quarter. Kalehua Capital Management LLC bought a new position in Aclaris Therapeutics during the first quarter valued at approximately $6,871,000. Finally, Palo Alto Investors LP bought a new position in Aclaris Therapeutics during the second quarter valued at approximately $8,535,045. Institutional investors own 98.34% of the company’s stock.

Key Aclaris Therapeutics News

Here are the key news stories impacting Aclaris Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.61 from $0.62 and its FY2027 estimate to a loss of $0.55 from $0.60. The firm also improved its quarterly 2027 forecasts, reflecting expectations for somewhat lower losses. HC Wainwright maintained a Buy rating and a $16 price target, substantially above ACRS’s recent trading level. HC Wainwright analyst estimates
• Positive Sentiment: HC Wainwright separately reaffirmed its Buy rating, reinforcing the analyst’s constructive view of Aclaris’s pipeline and longer-term prospects. HC Wainwright Reaffirms Buy Rating for Aclaris Therapeutics
• Neutral Sentiment: Aclaris discussed ATI-052 proof-of-concept results in atopic dermatitis and asthma. The update highlights ongoing pipeline development, but the available report does not provide enough detail to assess the results’ likely commercial or regulatory impact. Aclaris ATI-052 proof-of-concept results
• Negative Sentiment: Wedbush issued a pessimistic forecast for ACRS’s stock price, creating a counterweight to HC Wainwright’s bullish outlook and potentially contributing to weaker investor sentiment. Wedbush Issues Pessimistic Forecast for Aclaris Therapeutics

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.